Injectable in situ forming drug delivery system for cancer chemotherapy using a novel tissue adhesive: Characterization and in vitro evaluation

Injectable in situ forming drug delivery system for cancer chemotherapy using a novel tissue adhesive: Characterization and in vitro evaluation
复制标题

DOI:
10.1016/j.ejpb.2006.11.022
复制
发表时间:
2007-06-01
影响因子:
4.9
通讯作者:
Tateishi, Tetsuya
Tateishi, Tetsuya
中科院分区:
医学2区
文献类型:
--
作者:
Kakinoki, Sachiro;Taguchi, Tetsushi;Tateishi, Tetsuya

文献摘要

被引文献

相似文献

具有生物相容性和生物可降解性的可注射聚合物是药物输送系统和组织工程的重要生物材料。我们已经开发了由生物大分子和带有活性酯基的有机酸衍生物组成的新型组织粘合剂。所得到的组织粘附剂以凝胶的形式原位形成,对活体组织具有较高的粘合强度,并具有良好的生物相容性和生物降解性。在此,我们报道了这种由人血清白蛋白(HSA)和含有盐酸阿霉素(DOX)的酒石酸衍生物(TAD)组成的新型组织粘合剂的物理化学性质和体外评价。物化性能测试结果表明,HSA-TAD凝胶的凝胶化时间和凝胶强度可以根据材料组成进行控制。HSA-TAD胶粘剂的粘接强度足以在焦点处附着,并与HSA-TAD凝胶的交联度相对应。此外,在体外评价中,DOX从HSA-TAD凝胶中的释放持续了大约100it。因此,该新型组织粘合剂有望用作可注射的原位成型DDS。(C)2007 Elsevier B.V.保留所有权利。
Injectable polymers that are biocompatible and biodegradable are important biomaterials for drug delivery system (DDS) and tissue engineering. We have already developed novel tissue adhesives consisting of biomacromolecules and organic acid derivatives with active ester groups. The resulting tissue adhesive forms in situ as a gel and has high bonding strength for living tissue as well as it has good biocompatibility and biodegradability. Here, we report on the physicochemical properties and in vitro evaluation of this novel tissue adhesive consisting of human serum albumin (HSA) and tartaric acid derivative (TAD) containing doxorubicin hydrochloride (DOX). The results of the measurement of physicochemical characteristics indicate that the gelation time and gel strength of HSA-TAD gels can be controlled according to the material composition. The bonding strength of HSA-TAD adhesives was found to be sufficient to adhere at focus and to correspond with the cross-linking density of HSA-TAD gels. Furthermore, the release of DOX from HSA-TAD gels was sustained for approximately 100 It in an in vitro evaluation. The novel tissue adhesive, therefore, is expected to be applicable for use as an injectable in situ forming DDS. (c) 2007 Elsevier B.V. All rights reserved.